
    
      This study is a prospective, single-arm, non-randomized, open-label feasibility study to
      evaluate the safety of focal BBBD using the ExAblateÂ® 4000 Type 2 system. Up to 15 subjects
      with suspected infiltrating glioma who are scheduled to undergo brain tumor resection may be
      recruited for the study. Only patients that have a non-enhancing tumor components in a
      non-eloquent region of the planned standard-of-care resection volume will be eligible. Up to
      4 centers may participate in this study.
    
  